Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment

Overview

The purpose of this study is to investigate the effects of chronic elevated levels of Prolactin on metabolism and insulin sensitivity by studying patients with hyperprolactinemia before and after treatment.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2016

Interventions

  • Other: Cabergoline
    • Cabergoline 0,25 – 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.

Arms, Groups and Cohorts

  • Hyperprolactinemia
    • Patients recently diagnosed with hyperprolactinemia

Clinical Trial Outcome Measures

Primary Measures

  • Insulin sensitivity
    • Time Frame: Before and after treatment

Secondary Measures

  • QoL, body composition, intrahepatic and intramyocellular fat, substrate metabolism, glucose tolerance
    • Time Frame: Before and after treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Written consent – Age between 18 and 70 – At diagnose a serum prolactin > 200 microgram/l (10 U/l) Exclusion Criteria:

  • Hypothyroidism – Use of any medication – Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Aarhus
  • Collaborator
    • Aarhus University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jens Otto L. Jørgensen, Professor MD, Principal Investigator, Aarhus University Hospital, Department of Endocrinology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.